Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 2 (1): Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 4: | Line 4: | ||
|RefDocPart=Article 2 (1) | |RefDocPart=Article 2 (1) | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00019-Pri-Prü ++ TAG-00244-Def-ini ++ TAG-00135-Inv-ntr ++ TAG-00142-Mul-ent | ||
| | |RefModule=1 | ||
| | |RefUnit=1.5.4 | ||
}} | }} | ||
| Line 14: | Line 14: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 1 — Unit 1.5.4 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 30: | Line 33: | ||
| | | | ||
|- | |- | ||
! Tags | ! Tags | ||
| | | [[Glossary:TAG-00019-Pri-Prü|Principal investigator]], [[Glossary:TAG-00244-Def-ini|Definition]], [[Glossary:TAG-00135-Inv-ntr|Trial site]], [[Glossary:TAG-00142-Mul-ent|Multicentre trial]] | ||
|- | |||
| | |||
|- | |||
| | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 1 — Unit 1.5.4 |
| Scope | HM |
| Document part | Article 2 (1) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Principal investigator, Definition, Trial site, Multicentre trial |
| Comment | Definition of chief investigator |
Content
[...] “chief investigator” means— (a)in relation to a clinical trial conducted at a single trial site, the investigator for that site, or (b)in relation to a clinical trial conducted at more than one trial site, the authorised health professional, whether or not he is an investigator at any particular site, who takes primary responsibility for the conduct of the trial; [...]
